Bruce C. Gottwald, a director at NewMarket Corp, filed a Form 4 on September 10, 2026, reporting a disposition of 132 shares of common stock on September 9, 2026, via a gift transaction at a price of $0.00.
A Form 4 filed on September 10, 2026 discloses that Jennifer Ott Kozak, Senior Vice President and Chief Human Resources Officer of Armstrong World Industries Inc (NYSE:AWI), received two grants of restricted stock units on September 9, 2026 under the company's 2022 Equity and …
Jennifer Fulk, Chief Financial Officer of Kura Oncology, Inc. (NASDAQ:KURA), filed a Form 4 on September 10, 2026, reporting the acquisition of stock options covering 450,000 shares of common stock, with a transaction date of September 8, 2026.
Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corporation, filed a Form 4 on September 10, 2026, reporting the exercise of stock options and sale of common stock that occurred on September 9, 2026, pursuant to a pre-arranged Rule 10b5-1 trading plan.
A Form 4 filed on September 10, 2026, discloses that Manuel Pham Alvarez, a director of East West Bancorp Inc (NASDAQ:EWBC), sold 810 shares of common stock on September 8, 2026.
Amanda Kitzberger, Chief Legal Officer and Secretary of Hillman Solutions Corp. (NASDAQ:HLMN), filed a Form 4 on September 10, 2026, disclosing the sale of 13,750 shares of common stock on September 9, 2026.
Director Eddy W. Hartenstein filed a Form 4 with the SEC on September 10, 2026, reporting a transfer of 8,193 shares of Sirius XM Holdings Inc. common stock to the Hartenstein Family Trust, dated September 9, 2026.
Mary Elizabeth Henderson, SVP of Technical Operations at Jazz Pharmaceuticals plc (NASDAQ:JAZZ), filed a Form 4 on September 10, 2026, reporting the disposition of ordinary shares on September 8, 2026, to cover tax obligations from vesting restricted stock units.
Renee D. Gala, President and Chief Executive Officer of Jazz Pharmaceuticals plc (NASDAQ:JAZZ), filed a Form 4 on September 10, 2026, disclosing two transactions in ordinary shares dated September 8, 2026.
A Form 4 filed on September 10, 2026, disclosed that David R. Pelizzon, a director and 10% owner of OrthoPediatrics Corp, reported the sale of 302,369 shares of common stock on behalf of Squadron Capital LLC at a weighted average price of $21.01 per …